For CSF YKL-40, clusterin, fractalkine and MCP-1, high CSF levels are seen in cases with established tau-pathology (T+ or N+), regardless of amyloid status and seemingly independent of cognitive status, suggesting that links to tau, and not AD-specific pathology may be the main driver for these changes. This evidence concerns the gene MAPT and amyloidosis.